Danish 3D printing technologies company Create it REAL and Spentys, a Belgium company enabling mass tailor-made orthopaedic devices, join forces to accelerate 3D printing adoption at Certified Prosthetists and Orthotists (CPO’s) through a new partnership.
Spentys’ workflow, allows orthotists to streamline the development of 3d printed immobilisation devices. The company uses advanced artificial intelligence, cloud software, and 3d technology to advance state of the art in immobilisation devices. Spentys empowers medical experts globally to vastly improve the quality of care of their patients.
Create it REAL on the other hand has been developing customisable electronics and slicer software for the 3D printing industry. The team also recently launched a new encryption module and algorithms preventing industrial reverse-engineering as well as preventing 3D file piracy and guaranteeing file integrity.
“3D printed made-to-fit orthoses have many advantages for patients: they are lighter than traditional solutions, they are waterproof, and the open structure makes them more comfortable” said Florian De Boeck, Spentys’ co-founder.
“Today, we focus on in-house development of the immobilisation devices in our own R&D facility, but we’re now dead set on bringing on-demand 3D printing service lines to more orthotists through this partnership with Create it REAL. This will open up exciting pathways and enable orthotists to tap into previously unavailable technology and possibilities.”
The goal of this partnership is to develop and validate a 3D printing manufacturing pilot line of limb orthoses which in the end is meant to be installed at the practice of the CPO. “And that’s precisely why Spentys wants to work closely with CPO’s and offer a local 3D printing solution that will fit seamlessly into the orthotists current patient flow & workflow” Louis-Philippe Broze, co-founder & CEO of Spentys added.
Since 2017, Spentys has produced more than a thousand 3D-printed immobilisation devices in Belgium and is rapidly expanding its service to other countries in Europe, starting with the Netherlands, Switzerland, France and the UK. The partnership with Create it REAL will allow the development of a high-speed 3D printer that can be installed directly on the orthotists premises for faster delivery and cost-saving. Through advanced software technology, smart algorithms and Spentys’ user-friendly interface, orthotists will be able to scan, adjust and print from a simple user interface, all in their practice itself. The partnership will include implementation of Create it REAL’s electronic platform and REAL vision slicer software to increase the 3D printing process speed and security.
“There are many benefits for orthotists who are considering implementing on-demand 3D printing service lines” Louis-Philippe Broze says. “The streamlined orthoses workflow of Spentys significantly improves turnaround time by eliminating shipping. Quality control can be done onsite, and it allows orthotists within the same organisation to share knowledge and skills to handle complex cases and create innovative patient solutions.”
Jeremie Gay, Create it REAL’s CEO added: “We believe our platform can help companies like Spentys to build a customised solution to meet their customer’s needs. Most orthotists are not 3D printing experts and should not lose their time on the technical aspect. The technology complexity is hidden, and all parameters are defined automatically to get the best print. The reliability and speed are also essential to make sure the orthotist can offer an efficient 24/7 service.”
The system will also include a secured platform based on Create it REAL encryption solution. orthotists will be able to access the patient 3D scans and data securely while the orthosis 3D file will be encrypted to guarantee the file integrity during the whole process.
For more information on Spentys’ 3D printed medical solutions and questions regarding this study or our future studies, please check www.spentys.com or contact the team directly at info@spentys.com
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777455
